Literature DB >> 18675998

[Acute disseminated encephalomyelitis associated with hepatitis A virus infection].

B El Moutawakil1, M Bourezgui, M A Rafai, M Sibai, F Z Boulaajaj, F Moutaouakil, H Otmani, I Slassi.   

Abstract

INTRODUCTION: Hepatitis virus A (HVA) infection is usually a benign infection, but it can lead to severe manifestations and neurological symptoms. CASE REPORT: We report the case of a 44-year-old man who was admitted for pyramidal tetraparesis, loss of proprioceptive sensitivity and cranial nerve involvement. He had developed concomitally jaundice and fatigue. Brain MRI and cerebrospinal fluid examination were normal. Blood tests revealed elevated serum transaminase and anti-hepatitis A virus (IgM and IgG) levels. Acute disseminated encephalomyelitis (ADEM) was diagnosed and the patient was treated with high dose intravenous then oral corticosteroid therapy. The clinical condition continued to deteriorate and the patient died at eight months. DISCUSSION: ADEM is exceptionally associated with HVA infection or after vaccination for hepatitis A. Other neurological complications, including either peripheral or central nervous system, are reported. The clinical presentation and the outcome of our patient are atypical.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18675998     DOI: 10.1016/j.neurol.2007.09.003

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  Acute disseminated encephalomyelitis associated with Influenza A H1N1 infection.

Authors:  Jianxiu Wang; Shurong Duan; Jingkun Zhao; Liming Zhang
Journal:  Neurol Sci       Date:  2011-03-08       Impact factor: 3.307

Review 2.  Neurologic manifestations of gastrointestinal and liver diseases.

Authors:  José M Ferro; Sofia Oliveira
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

Review 3.  Management of Neurologic Manifestations in Patients with Liver Disease.

Authors:  José M Ferro; Pedro Viana; Patrícia Santos
Journal:  Curr Treat Options Neurol       Date:  2016-08       Impact factor: 3.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.